PrEP

Reports of modest success from two trials of tenofovir as pre-exposure prophylaxis against HIV - CAPRISA 004 relative risk reduction 39%; iPrEX RRR 44% - have inspired recent contributions to STI journal.

http://www.aidsmap.com/cat/1623/page/1404239/